Atlas Trials

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

Clinical trial NCT05168007 · UNKNOWN

Trial details

NCT number
NCT05168007
Sponsor
Whanin Pharmaceutical Company
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2021-11-19
Primary completion
2023-07-17
Enrollment
342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.